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Abstract. Asialoglycoproteins are taken up by the rat 
liver for degradation; rat polymeric IgA is taken up 
via a separate receptor, secretory component (SC), for 
quantitative delivery to bile. There is negligible uptake 
of these ligands by the converse receptor, and only a 
low level of missorting of ligands to opposite destina- 
tions. The two pathways are not cross-inhibitable and 
operate independently (Schiff, J. M., M. M. Fisher, 
and B. J. Underdown,  1984, J. Cell Biol., 98:79-89). 
We report here that when human IgA is presented as a 
ligand in the rat, it is processed using elements of both 
pathways. To study this in detail, different IgA frac- 
tions were prepared using two radiolabeling 
methods that provide separate probes for degradation 
or re-secretion. 
Behavior of intravenously injected human poly- 
meric IgA in the rat depended on its binding proper- 
ties. If deprived of SC binding activity by affinity ad- 
sorption or by reduction and alkylation, >80% of 
human IgA was degraded in hepatic lysosomes; radio- 
active catabolites were released into bile by a leupep- 
tin-inhibitable process. If prevented from binding to 
the asialoglycoprotein receptor by competition or by 
treatment with galactose oxidase, human IgA was 
cleared and transported to bile directly via SC, but its 
uptake was about fivefold slower than rat IgA. Un- 
treated human IgA was taken up rapidly by the asi- 
aloglycoprotein receptor, but depended on SC binding 
to get to bile: the proportion secreted correlated  I: 1 
with SC binding activity determined in vitro, and the 
IgA was released into bile with SC still attached. These 
results demonstrate that human IgA is normally heter- 
ovalent: it is first captured from blood by the asialo- 
glycoprotein receptor, but escapes the usual fate of 
asialoglycoproteins by switching to SC during trans- 
port. Since the biliary transit times of native human 
and rat IgA are the same, it is probable that the recep- 
tor switching event occurs en route. This implies that 
the two receptors briefly share a common intracellular 
compartment. 
URING its transport across the liver hepatocyte,  im- 
munoglobulin A (IgA)  ~  must be separated from other 
ligands being brought into the cell for degradation in 
lysosomes.  Entrance  into  the transcellular  and degradative 
pathways is mediated by distinct  receptors. The sorting step 
occurs either at the cell membrane or in an early intracellular 
compartment (39). This gives rise to an intriguing question: 
what would be the fate of a ligand able to bind to receptors 
for both pathways? One might predict a priori that the division 
of the ligand population would depend simply on the relative 
surface concentration  of the two receptors and their relative 
efficiency in capturing the ligand from the circulation.  How- 
ever, for the example studied in this paper, this turns out not 
to be the case. 
t Abbreviations  used in  this paper."  ASFet, asialo-fetuin; ASG, asialoglycopro- 
tein(s);  ASOr,  asialo-orosomucoid; BH,  Bolton  and  Hunter (reagent);  IgA, 
immunoglobulin A; HBP, hepatic binding protein (the ASG receptor);  HPLC, 
high pressure liquid chromatography; SC, secretory component. 
In the rat, transport  of autologous polymeric IgA intact to 
bile is a highly efficient process. Its receptor is the transmem- 
brane form of secretory component (SC) (28) present on the 
surface of the hepatocyte at ~200,000 molecules per cell (42). 
Intravenously  injected  rat polymeric  IgA is cleared rapidly 
from blood and appears  in bile ~30 min later (11,  19, 31). 
Transport  across the cell occurs primarily  via small vesicles 
(30, 36, 50); there is conflicting morphological  evidence re- 
garding the possible participation  of other intracellular organ- 
dies (14, 21). IgA binds to its receptor with high affinity: the 
cell must therefore sacrifice the receptor by polypeptide cleav- 
age in order to jettison the ligand at the canalicular face (23). 
To our knowledge, IgA is the only protein  endocytosed  by 
the liver that is primarily disposed by re-secretion across the 
cell. 
Since the liver plays an important physiological role in the 
regulation of protein balance in blood, many circulating pro- 
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include  lipoproteins, polypeptide hormones,  and  senescent 
plasma proteins. Perhaps the best studied model ligand for 
this pathway is asialoglycoprotein (ASG) (reviewed in refer- 
ences 1 and 49).  Its receptor is composed of 41,000-mol-wt 
subunits, which assemble into polymers in the plasma mem- 
brane (46). These receptors are at least as frequent on the cell 
surface as SC (41, 59, 60). Specific endocytosis is accelerated 
by ligand binding (6): it initiates a pathway that takes ASG 
through an acidic compartment and multivesicular bodies to 
secondary lysosomes, the terminal organelle where digestion 
occurs (7,  13, 47, 55). 
Because human IgA binds to rat SC in vitro, it is sometimes 
used  as  a  ligand  in  the  rat  hepatobiliary transport model. 
Unlike rat IgA, the natural substrate, human  IgA has been 
detected by electron microscopic autoradiography in multi- 
vesicular bodies and  lysosomes (20).  This prompted us to 
examine the possibility that human IgA could optionally use 
an alternative receptor to gain entry into the cell, and thereby 
into a different pathway. 
Our strategy was to perturb the ability of radiolabeled IgA 
to interact with hepatic protein receptors by affinity separa- 
tion, chemical alteration, or competition with unlabeled li- 
gands. We found that two different receptors, which normally 
mediate separate events, can both bind human  IgA.  These 
receptors participate cooperatively in the efficient transport 
of human IgA to bile. 
Materials and Methods 
Proteins 
Human monoclonal  polymeric IgA was isolated from the plasma of a patient 
with IgA l myeloma by ammonium sulfate and octanoic acid precipitation (10). 
IgG and minor impurities were removed by two rounds of chromatography  on 
DEAE  (diethylaminoethyl)  cellulose  using a  step  gradient  of NaC1 in  Tris 
buffer,  pH 8.0. Aggregates were removed  by gel filtration  on Sepharose 6-B 
(Pharmacia  Fine Chemicals,  Uppsala,  Sweden; 4.4  x  140 cm in phosphate- 
buffered saline [PBS]: 0.15 M NaCI, 0.01 M phosphate  buffer pH 7.4, 0.02% 
azide). Rat monoclonal IgA was derived from the ascites fluid of plasmacytoma 
line IR22, kindly provided by H. Bazin of the University of Louvain, Brussels. 
It was isolated  in a  similar  fashion,  except  that  only  one round of DEAE 
chromatography  was performed.  The polymeric fraction  was recovered on a 
2.6  x  90-cm Sepharose 6-B column. Human SC was isolated from colostral 
whey by affinity chromatography  on IgM Sepharose (52). Rat SC was isolated 
by a similar procedure,  from the Sephadex G-50 excluded fraction of pooled 
rat bile (manuscript  in preparation). 
For the  competition  experiments  shown in Figs. 5-7,  fetuin  was isolated 
from fetal calf serum according to the method described by Spiro (44). it was 
desialylated in 10 mM phosphate buffer, pH 6.1, by incubating on a rotator for 
2 d at 37"C with agarose-linked Clostridium perfringens neuraminidase  (type 
X-A, purchased from Sigma Chemical Co., St. Louis, MO). As detected by the 
thiobarbituric  assay  (56), this  resulted  in  the  release of 54%  of the  total 
hydrolyzable sialic acid. Parallel transport experiments  were conducted  with 
fetuin purified by ammonium sulfate fractionation  (32) (Sigma type III) and 
desialylated by acid hydrolysis (44). Competition  experiments using the differ- 
ent  Fet  and  ASFet  preparations  gave  compatible  results.  Purified  human 
orosomucoid was generously  donated  by  the  American  Red  Cross  Blood 
Products  Laboratory,  Bethesda, MD, and was desialylated by acid hydrolysis 
(44). 
Radiolabeling 
[t251]Bolton and Hunter (BH) reagent was purchased  from Amersham Corp., 
Arlington Heights, IL. Alternatively, [1251]BH reagent and [13q]BH reagent were 
prepared  by  labeling  N-hydroxysuccinimidyl  3(4-hydroxyphenyl)  propionic 
acid (Tagit; Calbiochem-Behring Corp., La Jolla, CA) using the chloramine-T 
method (4). The procedure was adapted for the t31I isotope by maintaining the 
same ratio of iodide/Tagit  in terms of milliCuries/micrograms  as described for 
t2~l (4). Labeling was carried out by drying 20-200  #Ci of the reagent in the 
bottom of a small test tube, adding  100 #g of protein in 200 #1 of 0.1  M Tris 
buffer (pH 8.0), and incubating at 0*C for 30 min. Unconjugated  reagent was 
removed from labeled IgA by dialysis against 0.85% saline that contained 0.1% 
glycine overnight at room temperature,  then against saline alone. The IgA was 
stored with 1 mg/ml human albumin in PBS, and dialyzed or redialyzed within 
3 wk before use in a transport experiment. BH-asialo-orosomucoid  (ASOr) was 
prepared  as  described  previously  (39). BH-protein  conjugate  preparations 
contained <4% free radiolabel, as determined by high pressure liquid chroma- 
tography (HPLC) analysis. 
To generate probes for the transcellular pathway alone, proteins were directly 
radioiodinated by the iodine monochloride method, using IC1 prepared in our 
laboratory  (16). Labeling  100  ~,g protein  gave specific activities of 10s-10 ~° 
cpm/mg  at a substitution ratio of  less than one atom of t25I or t3q per molecule. 
Free radioiodide was removed by exhaustive dialysis against PBS that contained 
0.075% NaI, and then PBS alone. Radioactivity was >98% precipitable in 15% 
trichloroacetic acid. 
Affinity Separation of  lgA Fractions 
Isolated human SC was coupled directly to BrCN-activated Sepharose (33, 40) 
at 1 mg SC/ml resin. Unreacted coupling groups were blocked with 40 mg/ml 
bovine  albumin  in  PBS. SC-binding  activity  was  removed  from purified, 
unlabeled human IgA by several passages over a 3-ml column of SC-Sepharose. 
After washing, the adherent fraction was recovered by elution with 1 M KSCN 
in 0.01 M potassium phosphate, pH 7.4, and then dialyzed. Labeled human or 
rat IgA preparations were fractionated by incubating in 1 ml PBS with  100 #1 
SC-Sepharose on a rotator in the presence of 1 mg unlabeled human albumin 
as carrier. The adherent  fractions were recovered from the washed adsorbant 
after a  1 h incubation,  while the activity in the supernatant  was passaged 2-4 
times  over  fresh aliquots  of SC-Sepharose for  further  depletion  of binding 
activity over 12-h periods. Each BH- and ICl-labeled fraction was prepared at 
least twice for use in the hepatobiliary transport experiments. 
Size fractionation  of non-adherent  human IgA was performed on an SW- 
3000 gel filtration HPLC column with a GSWP precolumn (LKB-Produckter 
AB, Bromma, Sweden). Samples were run at 1 ml/min in 0.85% saline, and l- 
ml aliquots were collected for counting. 2 ml from the ascending limb of the 
first peak  or from the descending limb of the  second  peak  constituted  the 
polymer and monomer fractions, respectively. Reduction and alkylation of the 
affinity  purified  fraction  were  performed  in  PBS  at  room temperature  by 
incubating  the  radiolabeled protein  for 1 h with  10  mM dithiothreitol,  and 
then with 2.5 equivalents of iodoacetamide  for 2 h. Treatment with galactose 
oxidase was done in azide-free PBS by the addition  of 5 U  of the  enzyme 
(Sigma type V, from Dactylium dendroides) to a 0.5-ml  solution  of labeled 
IgA, and incubation  at room temperature  overnight. This procedure has been 
shown elsewhere to prevent  human IgA from inhibiting  the ASG-receptor- 
induced  cross-linking  of galactose-bearing red  cells (48). Radiolabeled  lgA 
modified by either method was redialyzed against 0.85% saline before use in 
transport studies. 
Characterization of  the IgA Fractions 
Heavy and light chain content was determined  by polyacrylamide gel electro- 
phoresis in sodium lauryl sulfate (25). J chain content  was determined  by gel 
electrophoresis in an alkaline-urea  buffer system (35). Polymer content  was 
determined  by HPLC gel filtration on SW-3000 and SW-4000 columns stan- 
dardized with homogeneous IgA polymers of known composition. Immunoad- 
sorbants were prepared by coupling the IgG fraction of polyclonal monospecific 
sera  to BrCN-activated  Sepharose. Analytical  immunoprecipitation  and  SC 
binding experiments were conducted by adding a trace amount of labeled lgA 
to 10-60 ~l adsorbant  in PBS with  l  mg/ml bovine albumin as carrier. After 
incubation  at  room temperature  overnight  on a  rotator,  the  adsorbant  was 
centrifuged out and washed. Each preparation  was tested in triplicate. Within 
the  range used, the  percentage of label recovered in the  bound fraction was 
independent  of the concentration  of protein or adsorbant. 
Transport Studies 
Male Wistar rats (250-350 g: Charles River Canada, St. Contant,  Quebec) were 
maintained  on  lab  chow (Purina,  Mississauga, Ontario)  and  fasted 8-12  h 
before surgery. Under Nembutal anesthesia, cannulas were inserted in the bile 
duct, right femoral vein, and left iliac artery as described in detail in a previous 
publication (39). Use of PE-20 polyethylene tubing (Clay-Adams, Parsippany, 
N  J) for the iliac artery cannula enabled collection of individual blood samples 
within  5  s.  When  not in  use, the  cannula  was attached  to a  syringe that 
contained  150 USP units heparin (preservative-free Hepalean; Organon Canada 
Ltd., Toronto) per ml 0.875% saline. 
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tions,  labeled with opposite radioisotopes, were mixed and injected into the 
femoral vein, and bile was collected into preweighed tubes. The bile flow rate 
ranged from 7 to 21  eg/min. At appropriate time points, -75 ul of blood was 
withdrawn through the iliac cannula into a  l-ml syringe with directly attached 
27-gauge needle (Monoject, St. Louis, MO). The blood was transferred imme- 
diately to a plastic tube. and 50 ul was measured out accurately for counting. 
Leupeptin  inhibition  studies were performed  by  injecting  5 mg of drug  (9) 
(Sigma Chemical Co.) in 0.5  ml saline into the femoral  vein  1 h before the 
radioactive  sample.  Protein  competitors  (Fet,  ASFet, human  albumin,  or 
unfractionated  human polymeric IgA; 40-50 mg/ml in saline solution) were 
injected in two 0.5-ml boluses at 6 and 3 rain preceding the radioactive sample. 
Disposition of radiolabel in bile was determined  by gel filtration HPLC on 
an SW-3000 column.  The proportion  bound to intact IgA eluted at a position 
that corresponded to 100,000 mol wt or greater; radioactive catabolites eluted 
at the total column volume. 
Data were corrected by computer for isotopic overlap and radioactive decay. 
First,  clearance  half-times  (Table  I  and  Figs. 5 and  7)  were calculated  by 
measuring the activity present in the  l-rain blood sample, and logarithmically 
interpolating  between subsequent samples for the time required to reach half 
this level. For unfractionated  rat IgA preparations,  galactose oxidase-treated 
preparations, and in the competition experiments, a correction has been made 
in this calculation for the radioactivity that remained in blood at the end of the 
experiment (39). The post-injection time for each  10-rain bile aliquot (Fig. 5) 
has been plotted at the middle of the interval during which the collection was 
made, after a 2-5  min correction  for the cannula  dead volume. To generate 
the relative transport rate (% V~,: Figs. 6-7), the 150-min rate was compared 
with  the  peak  rate  by  computer in  units  of percent  injected  radioactivity 
transported  per  minute.  Standard  errors  for  %V~,~ were  calculated  using 
logarithmic values. P, the probability of equal means, was calculated using the 
one-tailed Wilcoxon nonparametric  rank sum test. 
Results 
Affinity Fractionation  of Human IgA on the Basis of 
SC Binding Activity 
IgA preparations contain a proportion of molecules that lack 
an ability to bind the receptor that mediates direct transport 
to bile (SC). The human IgA preparation used for this study 
possessed 0.5-0.7  SC binding sites per IgA dimer, although 
labeling  with  ICI  was  found  to  diminish  this  slightly.  To 
examine the  role  of SC  binding  in  IgA processing  in  the 
hepatobiliary transport model, human IgA was fractionated 
on SC Sepharose according to the scheme shown in Fig.  1. 
Radiolabeling  was  done  before  or  after an  initial  affinity 
purification step with similar results. The adherent phase from 
the first adsorption step consisted of >90% polymer and was 
70-85% enriched for SC binding activity. The non-adherent 
phase was incubated with fresh SC-Sepharose until the resid- 
ual binding activity was <10% of the surviving protein. Since 
monomeric IgA does not bind SC (27,  58), the non-adherent 
fraction was enriched for monomer (30-70% of the radiola- 
bel). For some experiments, the monomer and polymer com- 
ponents were separated by HPLC, and the polymer fraction 
was incubated once more over SC-Sepharose to deplete resid- 
ual binding activity. 
The BH-labeled human  IgA fractions were characterized 
extensively (40). All fractions showed similar heavy and light 
chain  composition,  and were 70-95%  precipitable with an 
immunoadsorbent specific for human alpha chain. The affin- 
ity purified fraction and  non-adherent polymer subfraction 
consisted primarily of dimer with <10%  monomer and no 
more than 20% higher polymers. They were indistinguishable 
by all criteria tested, except in the ability to bind SC. 
Two Possible Destinies for Human IgA in Rat Liver 
We were interested  in  following the  IgA fractions through 
both endocytic pathways: the direct transcellular pathway to 
bile and the degradative pathway that results in ligand diges- 
tion.  With  this  objective,  two  radiolabeling  methods  were 
used.  In some experiments, protein was radioiodinated with 
IC1 as a  direct indicator of the transcellular pathway: only 
protein-bound label is secreted into bile (39),  since free ra- 
dioiodide  from degraded  ligand  is  returned  to  blood (24). 
Alternatively, protein was conjugated with the BH reagent as 
a probe for both pathways: alongside any protein-bound label, 
radiocatabolites are secreted into  bile  in  proportion to  the 
amount of ligand degraded inside the  liver (39).  Transport 
studies were  initiated  in  anesthetized  rats  by injecting  the 
radiolabeled lgA preparations into the  femoral vein.  Blood 
was collected from the iliac artery to monitor ligand uptake, 
and bile was collected through a fistula of the common bile 
duct to monitor hepatic processing. Radioactivity present in 
bile was analyzed by gel  filtration HPLC to determine the 
proportion bound to intact protein. 
The character of transported radioactivity from these ex- 
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Figure 1. Strategy for fractionation 
of human IgA. The IgA was sepa- 
rated  into  affinity  purified  and 
non-SC-binding fractions before or 
after  labeling.  The  non-adherent 
fraction was subfractionated by gel 
filtration  HPLC, to prepare func- 
tionally  inactive  polymers  that 
were  otherwise  indistinguishable 
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similar experiments with ASOr, a functionally homogeneous 
protein taken up by the liver for degradation. Affinity purified 
human  IgA  was  transported directly to  bile,  reflecting the 
enrichment of SC binding activity in these fractions. Intact 
transport of human or rat IgA depleted of SC binding activity 
was limited, but a considerable proportion of the human IgA 
underwent degradation, as indicated by biliary release of BH- 
derived degradation products. The HPLC profile of radioac- 
tivity in bile showed two peaks: one corresponding to intact 
IgA, the other eluting at the total column volume. There were 
no  intermediate  peaks,  which  indicates  that  when  IgA  is 
subjected to digestion within the cell, the degradative process 
goes to completion. 
The kinetics of clearance and transport are presented in 
Table I.  All  human  IgA  preparations were cleared rapidly 
from blood,  regardless  of SC  binding activity. Monomeric 
preparations cleared significantly faster than did polymeric 
preparations. The clearance data  show why there were no 
catabolites released into bile from the non-SC-adherent rat 
IgA: this fraction was taken up poorly by the liver;  most of 
the activity had remained in blood. Apparently, only human 
IgA can be rapidly taken up into the degradative pathway. 
Transport to bile of the intact component (as indicated by 
the  ICl-labeled  probes) was  equally fast  for all human  IgA 
preparations (Table I). The time taken for human IgA to cross 
the cell was no longer than for rat IgA. However, the radio- 
activity from the BH-labeled non-adherent human IgA prep- 
arations (mostly catabolites) peaked in bile -20 min after the 
intact component. This is consistent with an additional time 
requirement for the ligand to be transported to lysosomes, 
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Figure 2. Transport of radiolabel to rat bile within  150 min, as a percentage of the injected dose. The solid area within each bar indicates the 
amount of radiolabel in bile attached to intact protein, determined by gel filtration HPLC. Release of radioactive catabolites from BH-labeled 
preparations  (striped  area)  reflects  ligand  degradation.  Unlike  rat  IgA,  SC-non-adherent  human  IgA  (both  polymers  and 
monomer) has the ability to enter the degradative pathway. Comparative data showing degradation of ASOr are from a  previous publication 
(39). (Each bar shows mean _+ SE for 4-6 experiments). E, total radiolabel in bile; m, protein-bound radiolabel in bile. 
Table I. Clearance and Transport  Kinetics 
BH-labeled preparations  ICl-labeled preparations 
Time of 
Blood clearance  Uncleared  Time of peak  Blood clearance  Uncleared  peak 
half-time*  after 1 h  transport  *  half-time*  after 1 h  transport  * 
rain  %  rain  rain  %  rain 
Human IgA 
Unfractionated  3.6-5.0  16  28 ___ 4  4.4-5.6  12  28 +  4 
Non-adherent fraction  2.9-4.8  16  47 +_ 3  2.7-5.8  15  30 ___ 2 
Non-adherent polymers  6.4-7.5  16  47 +_ 3  30 _  2 
Non-adherent monomer  1.8-2.7  15  44 -4- 5  34 ___ 4 
Affinity purified  2.7-4.2  2  30 --- 2  3.6-4.6  8  28 +_ 4 
Rat IgA 
Unfractionated  5.2-10.5  21  31  +__ 6  6.0-16.4  21  33 +. 3 
Non-adherent fraction  58  (103)  53  (37) 
ASOr  0.6-0.8  6 ~  40 +_ 4  0.7-0.8  13  §  25 _  2 
Italicized numbers show that ligands entering the liver primarily for degradation  take longer to be processed than ligands transported intact to bile. 
* Time to clear first 50%; range for 2-3 experiments. 
Mean -+ SE for 4-6 experiments, based on 10-rain collection intervals. 
Mostly degraded material released back into blood (53). 
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Figure 3.  (a) TranscetluIar transport.  1:!  correlation  between  SC- 
binding activity measured in vitro (abscissa), and the proportion  of 
human and rat IgA preparations reaching bile intact (ordinate). (Q, 
O) human IgA;  (&, &) rat IgA;  (×) ASOr. Open symbols indicate BH- 
labeled protein; solid symbols indicate protein labeled with IC1 (mean 
of _>4 animals). Horizontal and vertical whiskers indicate SE where 
sizeable in the respective determinations. (b) Degradation. Reverse 
correlation between SC-binding activity, and the proportion of label 
from  BH  human  IgA that  reaches bile as low  molecular weight 
catabolites. (c)  Effect of: reduction  and  alkylation on  the  affinity 
purified human IgA fractions. Subsequent to the loss of SC binding 
activity, the ligand is no longer transported to bile intact and reverts 
to processing by degradation. 
Table 11. Characterization of  Human IgA Transported 
to Bile 
lea before  lea trans- 
injection*  ported to bile  t 
Binding to immunoadsorbent  ~ 
Anti-human IgA 
Anti-rat SC 
Normal rabbit IgG 
Binding to human SC Sepharose 
90.0 --- 0.8%  92.5 +  2.7% 
5.0 -  0.7%  92.4 +  3.9% 
3.3 --- 0.8%  4.7 ___ 1.7% 
42.5 -4- 2.3%  1.9 __+ 0.6% 
* Unfractionated lCl-labeled human IgA.  Values given are  mean _+ SE  for 
three determinations. 
* Bile from transport experiments, dialyzed against two changes of PBS. Values 
given are  mean +_  SE  for  three determinations on  bile  from  each  of two 
transport experiments. 
+  Sepharose-linked  monospecific antibody or IgG control. 
degraded, and then for the catabolites to be taken to the bile 
canaliculus. 
Relationship  between SC Binding and the Fate of lgA 
in the Hepatocyte 
A  comparison  between  SC-binding  activity determined  in 
vitro, and the fate of the IgA fractions in the liver is made in 
Fig. 3. There was a direct correspondence between SC binding 
of either  human  or  rat  IgA and  transport  to  bile  via  the 
transcellular pathway (Fig.  3 a). On the other hand, degrada- 
tion of the human IgA, detected by release ofcatabolites from 
BH-labeled preparations, was reversely correlated with  SC- 
binding  activity  (Fig.  3b).  The  graph  extrapolates  back 
through SC non-adherent IgA preparations to the amount of 
catabolites released from BH-ASOr. This indicates that under 
certain  conditions,  almost  all  of the  human  IgA  can  be 
degraded. The transported and degraded proportions are com- 
plementary, i.e.,  those  IgA molecules that cannot bind  SC 
enter the degradative pathway by default, apparently by an 
independent receptor. 
Another way of  demonstrating the dependence of the trans- 
cellular pathway on SC binding is to show that the lgA actually 
becomes linked to SC during transport. This was tested by 
immunoprecipitation  of the  nondialyzable  radioactivity in 
bile (Table II): After transport, human lgA had no unoccupied 
SC binding sites (shown by loss of binding to SC-Sepharose), 
but became precipitable by immunoadsorbent specific for rat 
SC. 
Human IgA as a Heterovalent  Ligand 
The fact that degradation of human IgA occurs only in the 
absence  of  SC-binding  activity  provokes  the  question  of 
whether the SC-binding fraction has the ability to bind recep- 
tors  for both  pathways.  An  experimental  approach to  this 
question is to abolish SC-binding activity from affinity puri- 
fied  human  IgA,  to  see  if it  will  then  revert to  processing 
through  the  degradative pathway.  In  polymeric IgA, intra- 
monomer stabilization  relies partly on  noncovalent forces, 
but the only inter-monomer linkages are disulfide bonds (17). 
Mild  reduction  and  alkylation thus  provides a  convenient 
method for disassembling the polymer and destroying the SC 
binding site,  while leaving the monomeric substructure rela- 
tively intact. 
The effect of reduction and alkylation on hepatic handling 
of the affinity purified fractions is shown in Fig. 3 c. Reduced 
human lgA was still taken up efficiently by the rat liver:  the 
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1 h  after injection.  However, associated with the loss of SC 
binding activity was a concomitant decrease in the proportion 
of IgA transported directly to bile. The affected molecules had 
been successfully converted into ligands for the degradative 
pathway. 
This indicates that  before reduction,  the  affinity purified 
polymers had the potential to bind both SC and the receptor 
that mediated uptake for degradation. The ability to bind this 
alternative receptor is thus almost universally shared by all 
human  IgA molecules in  all  fractions.  In other words,  the 
molecules that possess an SC binding site are actually heter- 
ovalent. When SC binding activity is present, it is dominant 
in deciding the fate of the ligand. 
Degradation of  Human IgA in Lysosomes 
Lysosomal  function  can  be  blocked  by  administering  the 
cathespin inhibitor, leupeptin (9). The fate of human IgA in 
animals  pretreated  with  leupeptin  is  shown  in  Fig.  4.  In 
proportion to the non-SC-binding IgA present in each prep- 
aration,  BH  radiocatabolites were  secreted into  bile of the 
untreated  control  animals:  40-60%  for  non-adherent  frac- 
tions, and  10-20%  for the affinity purified fraction. Impair- 
ment of lysosomal function largely abolished catabolite secre- 
tion from these fractions, with a compensatory accumulation 
of radioactivity in the liver. In contrast, there was no statisti- 
cally significant decrease in the amount of IgA that reached 
bile intact. This implicates lysosomes as the site of degradation 
of the human IgA that cannot bind SC. Human IgA that can 
bind SC must bypass lysosomes in its pathway to bile. 
The ASG Receptor Mediates  Uptake of Human Ig,4 
into the Lysosomal Pathway 
The next task was to identify the receptor that gave non-SC- 
binding human IgA access to the degradative pathway. Re- 
cently, Stockert et al.  (48)  showed that  human IgAl  could 
bind to the ASG receptor in vitro. We therefore designed a 
series of inhibition experiments to test the involvement of the 
ASG receptor in human IgA processing by the rat liver. 
To study the kinetics of the two pathways separately, we 
prepared  two  radioligands  with  opposite  isotopes,  each  of 
which  primarily probes a  single  process:  non-adherent  BH 
human IgA for the ligand degradation pathway, and affinity 
purified IC1 human IgA for biliary transport via the transcel- 
lular pathway. These ligands were injected together into ex- 
perimental animals after prior infusion of a potential protein 
competitor.  Recovery from peak transport rate (% V~k)  at 
the end of the collection period was calculated as a sensitive 
kinetic indicator of inhibition, since the ability of the liver to 
complete secretion of radioactivity within the allotted time is 
impaired when transport events are delayed (39).  Clearance 
and transport curves from individual experiments are shown 
in Fig. 5; the total amount transported and the corresponding 
kinetic data are reported in Fig. 6. 
Results from the competition experiments demonstrate that 
the ASG receptor is responsible for allowing human IgA access 
to the degradative route: asialofetuin (ASFet), but not native 
fetuin,  blocked  the  uptake  and  processing of the  SC-non- 
adherent fraction. 
Surprisingly, the presence of  competing ASFet even affected 
the processing of SC-binding human IgA: clearance time from 
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Figure 4. Effect of leupeptin, the lysosomal protease inhibitor, on the 
transport  and  degradation  of BH  human  IgA. (-)  Saline-treated 
controls; (+) animals pretreated  1 h  before administration  of the 
radiolabeled sample with  5  mg leupeptin,  injected intravenously. 
After 3 h of bile collection, the livers were perfused with cold saline 
solution and  removed for counting.  The  proportion  of radiolabel 
bound to intact protein in bile was determined by HPLC. There is 
no  statistically significant reduction  in  intact  IgA transport,  but 
degradation of IgA is inhibited in all cases at P < 0.03. R/A,  reduced 
and alkylated. (Mean _+ SE; n = 3-5). 
blood of the affinity purified fraction was increased by 3.5- 
7.5-fold  (Fig.  5).  Even  though  the  SC-binding  activity did 
reach bile eventually, there was a corresponding delay in the 
median re-secretion time of 15  min (Figs.  5-6). This repre- 
sents a distinct departure from the behavior of rat IgA, which 
is not affected by the presence of excess ASFet. Thus, inhibi- 
tion by ASFet is highly specific for human IgA; it is not just 
due to long-range interdependence of the two receptor sys- 
tems. 
The ASG Receptor Also Participates in the Transport 
of  Human IgA to Bile 
Even though  binding  to  SC  is  still  essential for the  intact 
transport of IgA to bile, the ability of competing ASFet to 
delay the transport of heterovalent human IgA implicates the 
ASG receptor in this pathway as well.  The most immediate 
way to account for the  observed delay in  both uptake and 
secretion  is  to  suppose  that  the  ASG  receptor  is  directly 
responsible for capturing human IgA from blood. This can 
be tested a  second way, by enzymatically treating the  IgA, 
rendering it ineligible as a ligand for the ASG receptor. If the 
ASG receptor is not involved in IgA processing directly (i.e., 
if binding to SC is sufficient for efficient bile transport), then 
the modified IgA would be decoupled from inhibition effects 
of competing ASFet,  but would  still  be transported to bile 
rapidly. 
To diminish binding activity for the ASG receptor, labeled 
IgA preparations were treated  with  galactose  oxidase (48). 
Results of the subsequent transport experiments are shown in 
Fig.  7.  Treated non-adherent  human  IgA had  only limited 
access to either the transcellular or the degradative pathway: 
this was expected, since binding activity for both receptors 
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had been depleted. Treated rat IgA is the other control in this 
experiment: it was  cleared and transported to bile rapidly, 
showing that treatment with galactose oxidase did not affect 
functions mediated solely by SC. 
The  effect of galactose  oxidase  on  the  affinity purified 
human IgA fraction was twofold. First, it decoupled human 
IgA transport from inhibition effects of ASFet. Most impor- 
tantly,  it  resulted in  slower uptake and  subsequent biliary 
release of human IgA, similar to the delay induced by ASFet 
inhibition  of the  untreated  IgA  described  in  the  previous 
section. Nearly the entire complement of SC-binding activity 
could still reach bile using cell-surface SC directly, but this 
process was evidently much less efficient. To be cleared and 
transported to bile as rapidly as its rat counterpart, human 
IgA  has  an  absolute  requirement for binding to  the  ASG 
receptor. 
Figure  5.  Effect of competing proteins on  the 
clearance and transport of IgA in the rat. These 
are  representative curves  from  individual ani- 
mals injected with 40 mg of unlabeled potential 
competitor in  1 ml saline, 3-6 min before two 
radioligands with alternative isotopes. Non-ad- 
herent [~25I]BH human IgA probes the degrada- 
rive pathway, while affinity purified  ]3qCl  hu- 
man IgA probes the transcellular pathway deliv- 
ering human IgA directly to bile. In the control 
experiment  (a),  the  non-adherent  fraction 
cleared slightly faster than  the affinity purified 
IgA,  due  to  enrichment  for  IgA  monomers, 
which  have  more  direct  access  to  cell-surface 
receptors.  Excess  unlabeled  ASFet  (b)  blocks 
uptake into the degradative pathway and delays 
processing  of human  IgA in  the  transcellular 
pathway  (increasing  the  uptake  and  median 
transport times relative to the control, as indi- 
cated). There  is no effect of ASFet on  rat IgA 
processing (c). 
Discussion 
Competition for a Heterovalent Ligand between Two 
Receptors: Human IgA Switches Receptors Midstream 
Our observations show that the ASG receptor is intimately 
involved in the capture of human IgA from blood, regardless 
of its final disposition in the liver (Figs.  5-7). Competition 
with unlabeled ASG or treatment of the IgA with galactose 
oxidase delayed clearance of each human IgA fraction from 
the circulation by at least fourfold. This indicates that irre- 
spective of other receptor binding capacities borne by the 
ligand,  it is an initial association with the ASG receptor that 
is responsible for rapid  uptake by the liver cell.  The ASG 
receptor provides access  of human  IgA to the hepatocyte's 
lysosomal pathway; or alternatively, it facilitates  entry into 
the transcellular pathway, enhancing the kinetics of ligand 
secretion into bile. 
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Figure 6.  Effect of competing proteins on the amount of radiolabel 
that reaches bile, and the kinetics of transport. Radiolabeled probes 
and inhibitors were administered as in Fig. 5. (40 mg is ~0.1 #mol of 
human  IgA dimer  or  ~1  umol  of ASFet). Upper bars  show the 
amount of radiolabel that reaches bile within 150 min of injection. 
The solid area within each bar indicates the amount of radiolabel in 
bile attached  to intact protein,  determined  by HPLC. Lower bars 
indicate the ability of the liver to complete transport of the label to 
bile by the end of the experiment: %  V~d, (the transport rate at 150 
min relative to the peak rate) enables comparisons between experi- 
ments with the same radiolabeled probe, to detect kinetic inhibition. 
(Mean _ SE; n = 4). 
On the other hand, the fate of human IgA once captured 
by the cell still ultimately depends on its SC binding capacity. 
The evidence for this is twofold. First, the proportion of IgA 
in each fraction transported to bile intact always reflects the 
SC-binding capacity determined in vitro on a  1:1  basis (Fig. 
3a).  Human  IgA is  degraded  in  the  liver only by default. 
Second, virtually all IgA reaching bile acquires an ability to 
precipitate  with  anti-rat  SC  (Table  II),  i.e.,  it  retains  this 
receptor even after release from the cell.  The reduction and 
alkylation experiments showed that heterovalent human IgA 
is a perfectly good substrate for the degradative pathway, but 
by binding to SC, it can escape the usual fate of ASG. 
In  summary,  most  of the  human  IgA  reaching  bile  is 
captured initially by the ASG receptor, but essentially all of 
it ends up bound to SC. Taken together, these results provide 
the conclusion that the predominant mechanism for human 
IgA  transport  through  the  transcellular  pathway  requires 
switching of the ligand from one receptor to the other (Fig. 
8). There may be other occurrences in which receptor switch- 
ing plays a  critical role: for example, between the ASG and 
transferrin  receptors in  the  diacytosis pathway that  returns 
asialotransferrin to blood (34). As discussed below, the ability 
of receptors to cooperate in this fashion has implications for 
the ligand sorting process that occurs within the hepatocyte. 
Structural and Functional Differences between 
Human and Rat IgA 
The ASG receptor plays no role in the uptake and transport 
of rat  polymeric IgA; this  ligand  binds  directly to  SC.  In 
contrast, human IgA is almost homogeneous in being able to 
bind the  ASG receptor,  but  it cannot bind  directly to cell 
surface SC nearly as fast as its rat counterpart.  Thus,  both 
receptors detect important structural differences between hu- 
man and rat IgA. 
What we have referred to as the ASG receptor is undoubt- 
edly the hepatic binding protein (HBP), originally described 
by Hudgin et al. (18). In a hemagglutination inhibition assay, 
Stockert et at. (48)  showed that human IgA1  could bind the 
isolated HBP, but IgA2 could not. A  notable difference be- 
tween the IgA subclasses is the hinge region of IgA 1, which 
bears  short  serine-linked  oligosaccharides  terminated  with 
galactose (2). There is no homologous region in human IgA2. 
If this provides the site for HBP binding, then the failure of 
HBP  to  recognize rat  IgA is  understandable,  since  serine- 
linked carbohydrate is absent from the hinge region of IgA 
from lower mammals (37). 
We did  not anticipate that SC on the  hepatocyte surface 
would show a  kinetic preference for rat IgA. This is because 
(a)  SC  plays  an  important  physiological  role  in  man  by 
mediating efficient transport of locally produced IgA across 
the  mucosal  epithelium  (5);  and  (b)  in  vitro  assays  have 
indicated that human IgA binds human and rat SC equally 
well  (43).  Yet,  we  have  found  that  when  human  IgA  is 
prevented from interacting with the ASG receptor, it enters 
the rat liver via SC much more slowly than does rat IgA. This 
newly described ligand preference may be a previously unde- 
tected property intrinsic  to rat SC,  or an  effect of receptor 
presentation in the plasma membrane. 
Rapid Culture of  Human IgA by the ASG Receptor 
An important finding in this study is that heterovalent human 
IgA (which switches receptors) takes no longer to get to bile 
than  does rat  IgA (which  does  not).  This was reported  in 
Table I. For the kinetics of these two ligands to match, there 
are two requirements:  first,  the ASG receptor must capture 
human  IgA as rapidly as  SC captures rat IgA; second,  the 
receptor  switching  event  must  be  too  rapid  to  contribute 
significantly to the observed transit time. 
We have previously demonstrated a molecular weight siev- 
ing  effect  that  kinetically  impairs  access  of  molecules 
>100,000 mol wt to receptors on the hepatocyte surface in a 
size-dependent fashion  (38).  It is the sieving effect, not the 
direct rate of receptor coupling, that limits the rate at which 
both  human  and  rat  IgA clear from the  circulation.  Even 
treating human  IgA with  neuraminidase  does not  enhance 
the rate of hepatic uptake (unpublished data). Once human 
IgA bypasses the  sieve,  the  association rate  with  the  ASG 
receptor is  rapid,  perhaps just  as  rapid  as  other galactose- 
bearing proteins such as ASOr. 
Baenziger and Fiete (3) have pointed out that the isolated 
human IgA 1 hinge fragment binds to the HBP in vitro with 
only moderate affinity. In a  dynamic physiological context, 
the  forward rate is probably more important than  binding 
properties measured at equilibrium: Several hinge peptides in 
the whole IgA molecule (4 per dimer) may provide an avidity 
effect that  is  sufficient for maintaining the  ligand-receptor 
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5 L of galactose oxidase, to diminish binding activity far the ASG receptor. Unlabeled competing proteins were 1)readministered as described
in Fig. 5 . (heft) Clearance from blood of affinity purified human IgA in the presence of competing Fet (/) or ASFet (d), is compared with the
clearance of rat IgA (x) . (Mean t range ; n = 2) . (Right) The amount of label transported to bile, and the kinetics of transport . (Mean ± SE ., n
= 2-3) . K, SC binding ; M, transport to bile ; ", protein-bound radiolabel in bile .
complex on the hepatocyte surface until the next endocytic
event occurs. Even though primates also have a highly active
HBP, the circulating half-time ofthe same humanIgA protein
used here is >5h in the monkey (manuscript submitted for
publication) . The rapid capture ofhuman IgA by the rat liver
implies a fine specificity difference between the ratand human
HBP in their recognition ofthe responsible determinant .
Where Does Sorting between the Transcellularand
Degradative Pathways Take Place?
By using affinity techniques, we have been able to target
certain human I&A fractions to hepatic lysosomes . These
fractions were excellent substrates for lysosomal enzymes,
undergoing rapid and complete degradation . Blocking lyso-
somal enzymes with leupeptin did not augment transport of
intact IgA to bile, Thus, the notion that IgA reaches bile
simply by survivingdigestion (26) can be safely discarded . SC
must help sort IgA away from other ligands before most
proteolytic enzymes are introduced into the lysosomal path-
way .
In a previous paper (39), we considered in detail the sub-
cellular location where this sorting takes place . We demon-
strated that the transcellular anddegradative pathways diverge
either at the cell surface or in an early intracellular compart-
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ment. The failure of ASFet to inhibit rat IgA transport led us
to predict that the receptors for the two pathways were rarely
in juxtaposition on the cell surface . This was consistent with
the morphological data published by Jones and his colleagues
(21, 36) . By electron microscopic autoradiography, they
tracked radiolabeled rat IgA through endocytic vesicles that
bore different structural features from those involved in the
degradative pathway. They concluded that ligands with dif-
ferent destinations are endocytosed at the cell surface directly
into separate compartments . However, using a colloidal gold
immune overlay technique, Geuze et al . (14) recently identi-
fied IgA and ASG receptors together in tubular compartments
subjacent to the membrane . In apparent contradiction to the
work of Jones et al ., this group concluded that IgA and ASG
are brought into the cell together, and then sorted from each
other in an intracellular organelle .
The study presented here provides the ultimate resolution
ofwhere ligand sorting occurs. The observation that bears on
this issue is that the receptor switching event undertaken by
human IgA is too rapid to delay its transport to bile by a
detectable extent . This prohibits the possibility that human
IgA takes a more complicated pathway than rat IgA : for
example, endocytosis via the ASG receptor and recycling to
the plasma membrane for subsequent transfer to SC . Human
928Figure 8. Diagrammatic  summary of observations. (1) Asialoglycoproteins are cleared by a specific receptor (the hepatic binding protein) and 
enter the lysosomal pathway for degradation.  Rat IgA is recognized through its SC binding site (T), and enters an independent  pathway for 
direct transport to bile. Human polymeric IgA behaves in a similar fashion to rat IgA when binding to the ASG receptor is blocked (not shown), 
but the capture of human IgA by SC is much less efficient. (2) Human IgA monomers and polymers that have lost their SC binding site bind 
exclusively through carbohydrate determinants  to the ASG receptor and enter the lysosomal pathway. When the ASG receptor is blocked, these 
ligands remain  in blood. (3) Normally,  most untreated  human IgA polymers are heterovalent: they can bind both receptors. Their efficient 
clearance from blood relies on binding to the ASG receptor, but ligand destination still ultimately depends on an ability to bind SC. The fact 
that human IgA gets to bile as rapidly as its rat counterpart suggests that the receptor switching event occurs en route. Vesicular acidification 
induces a confirmational  change in the ASG receptor, and would promote switching of human IgA to SC for transport  to the bile canaliculus. 
This explanation  requires that the two receptors briefly share an intracellular compartment, after the acidification step but before the two ligand 
pathways diverge. 
IgA on its way to bile undoubtedly takes the same route as 
rat  IgA, but  switches receptors before the transcellular  and 
degradative pathways diverge. 
Under this constraint,  let  us consider the hypothesis that 
SC and the ASG receptor are endocytosed from the plasma 
membrane  into  completely  separate  compartments.  This 
would mean that human IgA would have to switch receptors 
at the cell surface in order to get to bile. The relative associa- 
tion rates with the two receptors imply that human IgA would 
spend most of its time with the ASG receptor, for which it is 
a potent inducer of endocytosis. It could only be transported 
quantitatively to the bile canaliculus if a specific mechanism 
existed to transfer the ligand to SC before this occurred. But 
the existence  of a  dedicated  switching mechanism is highly 
unlikely,  because  there  is  no  physiological requirement  for 
such a  mechanism: rat  IgA, the natural  substrate for biliary 
transport,  binds  to  cell-surface  SC directly.  In  short,  rapid 
transport of human IgA to bile is an unexplainable finding in 
the context of receptor separation at the plasma membrane. 
In  the  alternative  hypothesis,  that  the  transcellular  and 
degradative pathways diverge shortly after ligands enter the 
cell, these difficulties vanish. ASG is released from its receptor 
in an acidic compartment underneath the membrane (12,  15, 
51). The release is irreversible, because binding activity of the 
ASG receptor is acutely pH dependent (8, 54), and the recep- 
tor is recycled to the sinusoidal  membrane after decoupling 
(45, 57). In contrast, IgA-SC binding is stable down to pH 5 
(22,  58), and unoccupied receptors are continually shuttling 
from the sinusoidal membrane all the way to the bile canali- 
culus (29).  Under this  hypothesis,  then,  IgA could transfer 
between receptors in the acidic compartment (Fig.  8).  After 
decoupling from the ASG receptor, binding to SC would be 
facilitated  by  the  high  local  SC  concentration  inside  this 
compartment. If  the limiting factor was the transit time of SC 
across the cell,  then  the time  from endocytosis to secretion 
for human and rat IgA should match exactly. The morpho- 
logical data of Jones et al.  (21) can probably be reconciled 
with this sequence of events, providing the residency of IgA 
in the shared compartment is transient. 
The receptor switching phenomenon can evidently be ac- 
comodated in the subcellular sorting hypothesis, but is irrec- 
oncilable  with  the  cell  surface  sorting  hypothesis.  For  this 
reason,  our observations  provide  the  first  biochemical  evi- 
dence for sorting between  the transcellular  and degradative 
pathways inside the cell. 
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